The Nektar Therapeutics (NKTR) Shares Bought by Shelton Capital Management

The Nektar Therapeutics (NKTR) Shares Bought by Shelton Capital Management

Shelton Capital Management grew its stake in Nektar Therapeutics (NASDAQ:NKTR) by 12.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,283 shares of the biopharmaceutical company’s stock after purchasing an additional 1,696 shares during the period. Shelton Capital Management’s holdings in Nektar Therapeutics were worth $299,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Nektar Therapeutics by 14.1% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 692 shares during the last quarter. LS Investment Advisors LLC grew its position in Nektar Therapeutics by 8.8% in the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 535 shares during the last quarter. Flinton Capital Management LLC grew its position in Nektar Therapeutics by 75.7% in the 2nd quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 3,392 shares during the last quarter. Riverhead Capital Management LLC grew its position in Nektar Therapeutics by 78.7% in the 2nd quarter. Riverhead Capital Management LLC now owns 8,754 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 3,854 shares during the last quarter. Finally, Piedmont Investment Advisors LLC acquired a new stake in Nektar Therapeutics in the 1st quarter worth $216,000. Institutional investors own 95.08% of the company’s stock.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $24.20, for a total transaction of $2,016,658.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total transaction of $32,863.32. Following the sale, the senior vice president now owns 31,102 shares in the company, valued at $600,890.64. The disclosure for this sale can be found here. Insiders have sold 594,903 shares of company stock worth $13,547,340 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Several analysts have issued reports on the stock. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research report on Friday, August 18th. BidaskClub upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a research report on Monday, August 7th. They issued a “buy” rating and a $31.00 price target on the stock. Zacks Investment Research lowered shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Finally, William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $26.80.

Nektar Therapeutics (NASDAQ:NKTR) opened at 23.20 on Friday. The stock’s 50 day moving average is $22.48 and its 200-day moving average is $20.42. The company’s market capitalization is $3.63 billion. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $25.02.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The company’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.36) earnings per share. On average, equities analysts predict that Nektar Therapeutics will post ($0.98) earnings per share for the current fiscal year.

Nektar Therapeutics Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Related posts

Leave a Comment